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This study describes the first isolation and characterization of spontaneous mutants conferring natural
resistance to an antibiotic for any Bartonella species. The Bartonella bacilliformis gyrB gene, which encodes the
B subunit of DNA gyrase, was cloned and sequenced. The gyrB open reading frame (ORF) is 2,079 bp and
encodes a deduced amino acid sequence of 692 residues, corresponding to a predicted protein of ;77.5 kDa.
Sequence alignment indicates that B. bacilliformis GyrB is most similar to the GyrB protein from Bacillus
subtilis (40.1% amino acid sequence identity) and that it contains the longest N-terminal tail (52 residues) of
any GyrB characterized to date. The cloned B. bacilliformis gyrB was expressed in an Escherichia coli S30 cell
extract and was able to functionally complement a temperature-sensitive E. coli Cour gyrB mutant (strain
N4177). We isolated and characterized spontaneous mutants of B. bacilliformis resistant to coumermycin A1, an
antibiotic that targets GyrB. Sequence analysis of gyrB from 12 Cour mutants of B. bacilliformis identified single
nucleotide transitions at three separate loci in the ORF. The predicted amino acid substitutions resulting from
these transitions are Gly to Ser at position 124 (Gly1243Ser), Arg1843Gln, and Thr2143Ala or Thr2143Ile,
which are analogous to mutated residues found in previously characterized resistant gyrB genes from Borrelia
burgdorferi, E. coli, Staphylococcus aureus, and Haloferax sp. The Cour mutants are three to five times more
resistant to coumermycin A1 than the wild-type parental strain.
Recent taxonomic reclassifications involving bacteria for-
merly constituting the Rochalimaea and Grahamella genera
have rapidly expanded the number of species in the Bartonella
genus (5, 8, 10, 23, 47). Of these 12 species, 5 are presently
considered to be etiologic agents of emerging infectious dis-
ease in humans: Bartonella bacilliformis, B. clarridgeiae, B. eliza-
bethae, B. henselae, and B. quintana (22, 23, 33). Hemotrophy
and arthropod vector-mediated transmission are common par-
asitic strategies utilized by these small, gram-negative, faculta-
tively intracellular pathogens.
Due to the lack of a system for site-specific genetic manip-
ulation, few reports have been published concerning the mo-
lecular mechanisms involved in the pathogenesis, growth, and
antibiotic resistance of Bartonella species (3, 15, 16, 24, 27, 29,
31, 34, 42, 46, 49). Therefore, we initially address this problem
by molecularly characterizing the pathogens’ gyrB gene. DNA
gyrase is the bacterial type II topoisomerase responsible for
introducing negative supercoiling into DNA (reviewed in ref-
erences 20 and 37), and it is the target of several types of
antimicrobial agents. The holoenzyme is an A2B2 complex
encoded by the gyrA and gyrB genes; the A subunit is respon-
sible for DNA breakage and reunion, whereas the B subunit
harbors the ATP binding site. The coumarin antibiotics
coumermycin A1, novobiocin, and chlorobiocin impede DNA
replication by inhibiting the ATP binding and hydrolysis cata-
lyzed by GyrB (28). Several reports have demonstrated that
single point mutations in the gyrB gene confer resistance to
coumarin antibiotics (11, 13, 19, 36, 39, 44) providing a locus
and selectable phenotype for allelic exchange experiments.
In this study, we describe the isolation and characterization
of the first spontaneous mutants of any Bartonella species, as
well as the first characterization of an antibiotic-resistant mu-
tant. Analysis of coumermycin A1-resistant mutants revealed
single nucleotide lesions corresponding to specific amino acid
substitutions in the N-terminal domain of GyrB. These muta-
tions confer an approximately three- to fivefold increase in the
MIC of coumermycin A1 relative to the wild type. In addition,
we show that the B. bacilliformis gyrB can functionally comple-
ment an E. coli gyrB mutant. Finally, we discuss the positions of
the amino acid substitutions in B. bacilliformis GyrB as they
relate to recently solved high-resolution crystal structures and
enzyme function (26, 48).
MATERIALS AND METHODS
Bacterial strains and culture conditions. E. coli strains were grown overnight
at 37°C in Luria-Bertani (LB) medium with standard antibiotic supplements
when required (12). B. bacilliformis was grown and harvested as previously
described (34).
To isolate coumermycin A1-resistant mutants, suspensions of B. bacilliformis
KC583 were plated on heart infusion agar supplemented with 5% erythrocytes
and coumermycin A1 (0.1 mg/ml; Sigma Chemical Co., St. Louis, Mo.). Coumer-
mycin A1-resistant mutants were usually observed after 5 days of growth and
were harvested after 7 days. Resistant colonies were picked and resuspended in
150 ml of heart infusion broth. Resistant mutants were maintained in the pres-
ence of 0.04 mg of coumermycin A1 per ml. Strains of B. bacilliformis and
Escherichia coli used or generated in this study are summarized in Table 1.
Preparation and manipulation of DNA. Chromosomal DNA from B. bacilli-
formis for use in DNA hybridization or PCR analyses was prepared with CTAB
(hexadecyltrimethyl ammonium bromide) by the methods of Ausubel et al. (2).
Plasmid DNA extraction and isolation from E. coli for cloning were performed
by the alkaline lysis procedure of Birnboim and Doly (4), and plasmid prepara-
tions for sequencing were made with either a Midi-Prep kit (Qiagen, Chatsworth,
Calif.) or a Perfect Prep kit (5 PRIME-3 PRIME, Boulder, Colo.) as per the
manufacturer’s instructions. Cloning of individual DNA fragments was accom-
plished by two distinct methods. First, both l-ZAP Express (Stratagene Cloning
Systems, La Jolla, Calif.) and l-GEM 11 (Promega, Madison, Wis.) genomic
cloning systems were used as per the manufacturer’s recommendations to obtain
phagemid clones containing the B. bacilliformis gyrB gene for sequence analysis.
Second, the TOPO TA Cloning Kit (Invitrogen, Carlsbad, Calif.) was used as per
the manufacturer’s instructions to obtain a plasmid clone containing the entire
wild-type gyrB open reading frame (ORF) for gene expression and functional
complementation analyses. When required, DNA was purified from ethidium
bromide-stained agarose gels or PCRs with either a GeneClean kit (Bio 101, Inc.,
La Jolla, Calif.) or by a QIAquick kit (Qiagen). Plasmids and recombinants used
or constructed in this study are summarized in Table 1.
* Corresponding author. Mailing address: Division of Biological Sci-
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PCR and oligonucleotides. PCR amplifications were achieved by using a Gene-
Amp 2400 Thermocycler (Perkin-Elmer, Norwalk, Conn.) following procedures
developed by Mullis et al. (35). Reaction mixtures contained 10 mM Tris-HCl
(pH 8.3), 50 mM KCl, a 200 mM concentration of each deoxynucleotide triphos-
phate, 4 mM MgCl2, 2.5 U of AmpliTaq DNA polymerase (Roche Molecular
Systems, Branchburg, N.J.), 1 to 100 ng of template DNA, and 0.1 mg of each
primer. The reaction proceeded for 30 cycles of 1 min at 94°C, 1 min at 50 to 60°C
(depending on calculated primer melting temperature), and 1 min at 72°C, with
an initial 5-min denaturation at 94°C and a final 7-min extension at 72°C.
Single-stranded degenerate oligonucleotide primers (based on regions of con-
served homology [21]), GYRB5 (59-AARMGNCCNGGNATGTAYATHGG-
39) and GYRB3 (59-CCNACNCCRTGNARNCCNCC-39), were synthesized by
Gibco-BRL. Single-stranded oligonucleotide primers specific for the B. bacilli-
formis gyrB gene included the following: GYRB-F, nucleotide (nt) 2219 to 2187
(59-CGCGGATCCCTGCGGAATAACAAATCATGGTG-39); GYRB-R, nt
132 to 100 (59-CGCGGATCCTATCGATAAAACGATCCATCTGGC-39); LE-
SION-F, nt 307 to 331 (59-GCTGATTTGATTGATATAACATTGG-39), and
LESION-R, nt 711 to 688 (59-TATAAATTTTTTCTGGGTCAAAAGC-39).
DNA hybridization analysis. Total DNAs from B. bacilliformis KC583 and
KC584 and E. coli HB101 were isolated, digested to completion with BamHI, and
then separated on an ethidium bromide-stained 1% (wt/vol) agarose gel. The gel
was then blotted onto a nitrocellulose membrane (0.45-mm pore size; Schleicher
& Schuell, Keene, N.H.) by the method of Southern (43) and baked for 1 h at
80°C. The 2,410-bp fragment used as the probe in this analysis was derived by
PCR amplification using the amplimer set GYRB-F–GYRB-R and B. bacillifor-
mis KC583 as template DNA. This 2,410-bp PCR fragment was subsequently
labeled by random primer extension (14) with the Klenow fragment of E. coli
polymerase I (Gibco-BRL) and [a-32P]dCTP (New England Nuclear, Boston,
Mass.). The blot was probed overnight at 50°C with the 32P-labeled 2,410-bp
PCR fragment and then was washed and visualized as previously described (32).
DNA hybridization was also used for probing two separate l genomic libraries
to clone and sequence the gyrB gene. In these experiments, either the 300-bp
PCR product derived from the degenerate amplimer set GYRB5-GYRB3 or the
internal 1,101-bp HindIII fragment was labeled by random primer extension and
used to screen the libraries.
In vitro transcription-translation. Expression of gyrB was done using an E. coli
S30 cell in vitro transcription-translation system per the manufacturer’s instruc-
tions (Promega). 35S-labelled proteins were visualized by sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (25) and autoradiography as previously de-
scribed (34).
In vivo complementation analysis. A plasmid containing the cloned gyrB
(pGYRB3) and the respective cloning vector (pCR2.1-TOPO) were separately
introduced into strains N99 and N4177 by modifying the transformation proce-
dure of Chung et al. (9) such that the culture temperature of N99 and N4177 was
held below 30°C throughout the transformation procedure. Transformed clones
of N99 or N4177 containing either pGYRB3 or pCR2.1-TOPO plasmids were
selected by incubation at 30°C for 16 h in the presence of ampicillin (100 mg/ml).
Immediately thereafter, clones of each of the four transformants (N99[pCR2.1-
TOPO], N99[pGYRB3], N4177[pCR2.1-TOPO], and N4177[pGYRB3]) were
simultaneously replica plated onto LB (supplemented with ampicillin [100 mg/
ml]), and incubated at either 30°C (permissive temperature) or 42°C (restrictive
temperature) for 20 h. Both E. coli host strains (N99 and N4177) were replica
plated onto LB and LB-ampicillin (100 mg/ml) simultaneously for additional
positive and negative controls, respectively. Replica-plated clones were scored
after 20 h of growth by estimating relative colony size.
Antibiotic susceptibility testing. MICs were determined by two methods. Ini-
tial determination of the MIC of coumermycin A1 for the wild type was achieved
by plating 100 ml of Bartonella suspensions containing 105 CFU/ml on heart
infusion agar supplemented with 5% erythrocytes and coumermycin A1 concen-
trations ranging from 0.01 to 1.0 mg/ml. Second, determination of the MICs for
Cour mutants was accomplished by an agar dilution technique previously de-
scribed for Bartonella (27). Briefly, resistant strains were harvested after 5 days
of incubation, washed, and resuspended in phosphate-buffered saline (pH 7.5).
The suspensions were then equilibrated to a McFarland 0.5 standard at an
optical density at 600 nm. Aliquots (10 ml) were applied to heart infusion agar
supplemented with 5% erythrocytes and coumermycin A1 concentrations of 0.1,
0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, and 1.0 mg/ml. The MIC is defined as the
concentration of coumermycin A1 at which no growth is detected following 7
days of routine incubation. MICs were obtained by three independent determi-
nations.
Nucleotide sequencing and computer analysis. The inserts of overlapping
clones derived from l-ZAP Express (pGYRB1) and l-GEM 11 (pGYRB2)
genomic libraries were sequenced separately to obtain the nucleotide sequence
for the entire gyrB gene. Templates were primed with M13 universal primers or
with synthetic oligonucleotides prepared with a DNA synthesizer (model 394;
Applied Biosystems, Foster City, Calif.). The nucleotide sequences for both
DNA strands of the gyrB gene were then determined by the dideoxy chain-
termination method of Sanger et al. (41) using a Taq DyeDeoxy Terminator
Cycle Sequencing Kit as per the manufacturer’s instructions (Applied Biosys-
tems). Sequencing was done on an Applied Biosystems Automated DNA Se-
quencer (model 373A). Sequence data were compiled and analyzed by using
PC/GENE 6.8 software (Intelligenetics, Mountain View, Calif.) for restriction
site determination and ORF identification, BLAST (1) for database searches,
CLUSTAL W 1.6 (45) for multiple sequence alignments, and BOXSHADE 3.21
(18) for sequence alignment formatting.
Nucleotide sequence accession number. The GenBank accession number for
the Bartonella bacilliformis gyrB nucleotide sequence is U82225.
RESULTS
Cloning the gyrB gene. Two clones were required for se-
quence analysis of this gene. A positive plaque with the cloned
B. bacilliformis gyrB gene was isolated from a l-ZAP Express
library (Stratagene) by probing with a [a-32P]dCTP-labeled
300-bp PCR product generated from B. bacilliformis KC583
template DNA by using the degenerate oligonucleotide prim-
ers GYRB5 and GYRB3. A pBK-CMV phagemid clone was
excised from the l-ZAP Express clone and termed pGYRB1.
Nucleotide sequence analysis revealed that only the 59 portion
(1094 bp) of the gyrB gene was present in the ;2,000-bp
Sau3AI insert of pGYRB1.
To obtain the remainder of the sequence for gyrB, the
1,101-bp HindIII fragment of pGYRB1 containing the 59 por-
tion of the gyrB gene was labeled by random primer extension
and used to probe a l-GEM 11 genomic library (Promega) in
hopes of obtaining a l clone with a larger insert containing the
entire gyrB gene. A second l clone was identified and found to
contain the entire gyrB gene in an ;13-kbp SacI fragment by
DNA hybridization. The SacI fragment was excised and cloned
into pBK-CMV to generate pGYRB2. The insert in pGYRB2
was used to complete the nucleotide sequencing of the wild-
type B. bacilliformis gyrB gene.
The complete gyrB gene (2,410 bp) was amplified from B.
bacilliformis KC583 DNA by using the amplimer set GYRB-
TABLE 1. Bacterial strains and plasmids used in this study
Strain or plasmid Relevant characteristic(s) Source orreference
B. bacilliformis
KC583 Wild-type strain 7
CR1, 2, 6, 8, 9 KC583 GyrB(Gly1243Ser) Cou
r This study
CR4, 7, 11, 12 KC583 GyrB(Arg1843Gln) Cou
r This study
CR3 KC583 GyrB(Thr2143Ala) Cou
r This study
CR5, 10 KC583 GyrB(Thr2143Ile) Cou
r This study
E. coli
HB101 Host strain used for cloning 6, Promega
TOP10F9 TOPO TA Cloning Kit host strain Invitrogen
N99 Complementation analysis strA galK 30
N4177 Isogenic to N99 except gyrB221
(Cour) and gyrB203 (TS)
30
Plasmids
pBK-CMV Phagemid cloning vector Stratagene
pCR2.1-TOPO Cloning vector Invitrogen
pGYRB1 pBK-CMV recombinant containing
59 portion of B. bacilliformis gyrB
in an ;2,000-bp Sau3AI
fragment; derived from l-ZAP
library
This study
pGYRB2 pBK-CMV recombinant with an
;13-kb SacI fragment containing
the B. bacilliformis gyrB; derived
from l-GEM 11 library
This study
pGYRB3 pCR2.1-TOPO recombinant
containing entire gyrB gene in a
2,410-bp BamHI fragment;
derived from TA cloning strategy
This study
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F–GYRB-R and cloned into pCR2.1-TOPO. This gyrB recom-
binant was designated pGYRB3.
Nucleotide sequence of the gyrB gene. The nucleotide se-
quence of the wild-type (coumermycin A1-sensitive) B. bacil-
liformis gyrB gene was determined from both DNA strands and
is presented in Fig. 1. Computer-assisted analysis of the gyrB gene
showed a 2,079-bp ORF. This ORF is characterized by a com-
mon initiation codon, ATG, that is preceded by putative 235
(TTCAAA) and 210 (GATAAT) consensus regulatory ele-
ments and a potential ribosomal binding site (AGTA) (Fig. 1).
Further analysis of the ORF indicated that the encoded
protein had a deduced length of 692 amino acid residues and
a predicted molecular mass of approximately 77.5 kDa.
BLAST (1) homology searches indicate that B. bacilliformis
GyrB is most similar to Bacillus subtilis GyrB, with an amino
acid sequence identity of 40.1%, whereas B. bacilliformis GyrB
has only 18.4% identity with B. subtilis ParC, a GyrB homolog.
The B. bacilliformis subunit has 34.1% identity with E. coli
GyrB. Alignment of the deduced amino acid sequence from B.
bacilliformis gyrB with the known amino acid sequences of
GyrBs from E. coli, B. subtilis, and Mycobacterium tuberculosis
(using CLUSTAL W 1.6) indicates multiple areas of strong
homology (Fig. 2) and reveals that the B. bacilliformis GyrB
has an unusually long N terminus. Sequence analysis of ;600
bp of flanking sequence indicate a possible gene upstream of
gyrB with homology to lipoate-protein ligase B, whereas 39
flanking sequence produces no areas of strong homology to
database sequences (data not shown).
DNA hybridization analysis. In order to verify that the gyrB-
containing fragment was of Bartonella origin, DNA hybridiza-
tion analysis was done with BamHI-digested DNA from B.
bacilliformis strains KC583 and KC584 and from E. coli
HB101. As shown in Fig. 3B, Southern blots probed at high
stringency (7% mismatch) with a 32P-labeled 2,410-bp PCR
fragment derived from B. bacilliformis KC583 template (by
using amplimers GYRB-F and GYRB-R) clearly demon-
strated single hybridization bands from both strains of B. ba-
cilliformis (Fig. 3B, lanes 3 and 4). No signal was observed in
BamHI-digested E. coli HB101 DNA (Fig. 3, lane 2). In addi-
tion, the G1C content of the ORF (38.4 mol%) is in good
agreement with the overall G1C content (39 mol%) of B.
bacilliformis (7).
In vitro expression of gyrB. To determine if E. coli transcrip-
tion-translation machinery would express the cloned B. bacil-
liformis gyrB, an E. coli S30 cell DNA expression kit (Promega)
was used to produce polypeptides in vitro. Sodium dodecyl
sulfate-polyacrylamide gel electrophoresis analysis of proteins
expressed from pGYRB3 revealed a protein product consis-
tent with the predicted molecular mass for GyrB of 77.5 kDa
that was not expressed from the pCR2.1-TOPO control by this
system (data not shown). The 77.5-kDa protein was the largest
protein encoded, although additional insert-specific protein
bands of approximately 68, 65, 52, and 38 kDa were observed
and may have been produced by the E. coli S30 extract from
anomalous ORFs on the noncoding strand of pGYRB3 or may
be degradation products.
Functional complementation analysis. Since the S30 extract
expressed the cloned gyrB, an isogenic pair of E. coli strains
first described by Menzel and Gellert (30) was used to evaluate
the in vivo function of the cloned B. bacilliformis gyrB. E. coli
N99 carries a wild-type gyrB, and strain N4177 has two gyrB
mutations, which together confer a coumermycin A1-resistant
(Cour) and temperature-sensitive (TS) phenotype. Growth of
strain N4177 is permissive at 30°C but is restricted at 42°C
unless a functional gyrB is supplied in trans to complement the
Cour TS mutation. Therefore, we wanted to determine whether
B. bacilliformis gyrB could functionally complement strain
N4177. To address this question, the B. bacilliformis gyrB re-
combinant pGYRB3 was introduced into strains N99 and
N4177, selected at 30°C, and subsequently replica plated and
separately incubated at both permissive (30°C) and restrictive
(42°C) temperatures. The B. bacilliformis gyrB recombinant,
pGYRB3, was shown to increase the growth rate of strain
N4177 at 42°C by approximately threefold relative to negative
controls (Table 2). The presence of plasmids or varied incu-
bation temperature did not affect the relative growth rates of
host strain N99. The pattern of growth for this analysis was
consistent and reproducible and shows that B. bacilliformis
gyrB can functionally complement the Cour TS mutation of E.
coli N4177.
Isolation of coumermycin A1-resistant mutants. Spontane-
ous coumermycin A1-resistant mutants were observed 7 days
after inoculation and occurred at a frequency of ;6 3 1029
when selected in the presence of 0.1 mg of coumermycin A1 per
ml. After initial selection, mutant strains were cultured on heart
infusion agar supplemented with 0.04 mg of coumermycin A1
per ml. A total of 12 B. bacilliformis KC583 coumermycin-
resistant mutants were selected in this manner and designated
CR1 through CR12 (Table 1). In the absence of coumermycin
A1, the growth rate and gross morphology of the Cou
r colonies
were indistinguishable from those of wild-type strains.
Coumermycin A1 resistance is correlated with mutations in
the gyrB gene. Genomic DNA was isolated from wild-type B.
bacilliformis KC583 and the 12 coumermycin A1-resistant mu-
tants. The region of the gyrB gene encoding the N-terminal
domain was amplified by PCR with LESION-F and LE-
SION-R primers and subsequently sequenced with the LE-
SION-F primer. Further analysis of these sequences revealed
single nucleotide transitions at three separate loci that resulted
in four distinct amino acid substitutions. First, in 5 of the 12
coumermycin A1-resistant strains (CR1, CR2, CR6, CR8, and
CR9), identical G-to-A transitions at base 370 of the 2,079-bp
ORF resulted in a deduced Gly124-to-Ser (Gly1243Ser) sub-
stitution. Second, 4 of the 12 resistant strains (CR4, CR7,
CR11, and CR12) carried a G-to-A transition at base 550 that
resulted in a deduced Arg1843Gln substitution. The third loci
at which lesions were detected occurred in the Thr214 codon,
in which two different transitions were observed with two dis-
tinct deduced substitutions; the ACA-to-GCA transition re-
sulted in a Thr2143Ala substitution (CR3), whereas the
ACA-to-ATA transition resulted in a Thr2143Ile substitution
(CR5, CR10). These data demonstrate that spontaneous
coumermycin A1-resistant mutants are correlated with specific
and localized lesions in the gyrB gene. Table 3 summarizes
several genotypic and phenotypic attributes of the coumermy-
cin A1-resistant strains.
In vitro coumermycin A1 susceptibilities. We assessed the
antibiotic susceptibility of wild-type B. bacilliformis KC583 to
coumermycin A1 by using agar dilution techniques. At coumer-
mycin A1 concentrations above 0.03 mg/ml, growth rates were
noticeably decreased, and at those above 0.06 mg/ml, growth
appeared to be completely inhibited. Thus, the MIC for KC583
was determined to be 0.06 mg/ml. One representative of each
of the four different gyrB mutant types was assayed for coumer-
mycin A1 susceptibility. MICs for mutant strains CR3, CR4,
and CR9 were 0.2 mg/ml, whereas CR5 demonstrated a slightly
higher level of resistance, with a MIC of 0.3 mg/ml (Table 3).
DISCUSSION
We have described the first isolation and molecular charac-
terization of spontaneous mutant strains conferring natural
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FIG. 1. Nucleotide and predicted amino acid sequence of B. bacilliformis gyrB. The nucleotide sequence of a 2,250-bp fragment containing the wild-type
coumermycin A1-sensitive B. bacilliformis gyrB is shown. Nucleotides within the 2,079-bp ORF are given in uppercase letters, and the deduced 692-residue amino acid
sequence is shown below each corresponding codon. Putative consensus regulatory elements are indicated (235, 210, ribosomal binding site [RBS]). The stop codon
is marked with an asterisk. The three codons (and their corresponding amino acids) in which single nucleotide substitutions resulting in coumermycin A1 resistance
were found are boxed. The unusually long 52-residue N terminus is shown in boldface type. The predicted molecular mass of the mature protein is 77.5 kDa. The
GenBank accession number for the gyrB gene is U82225.
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resistance to an antibiotic for any Bartonella species. Genera-
tion of the mutant strains was accomplished by exposure to
inhibitory (0.1-mg/ml) levels of the DNA gyrase inhibitor
coumermycin A1 and occurred at a frequency of ;6 3 10
29.
Based upon amino acid sequence alignments, B. bacilliformis
GyrB belongs to the shorter, 650-amino-acid size class repre-
sented by homologs of enzymes from B. subtilis, Mycoplasma
pneumoniae, Staphylococcus aureus, Borrelia burgdorferi, and
FIG. 2. Multiple alignment of B. bacilliformis GyrB with B. subtilis, E. coli, and M. tuberculosis GyrB. Multiple alignment of B. bacilliformis GyrB (Barba) with B.
subtilis GyrB (Bacsu), E. coli GyrB (Ecoli), and M. tuberculosis (Myctu) generated with CLUSTAL W 1.6 (45) and formatted with BOXSHADE 3.21 (18). Identical
amino acid residues are shown as white on black, conserved residues are shown as black on grey, and introduced gaps are shown as dots. Note the unusual 53-residue
N-terminal extension that is similar in length to the N terminus of M. tuberculosis GyrB. The first universally conserved residue (E. coli of Tyr5) is indicated by the
arrowhead. GenBank accession numbers for these GyrB sequences are U82225 (B. bacilliformis) D26185 (B. subtilis), AE000447 (E. coli), and X78888 (M. tuberculosis).
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Haloferax sp. (20). In the larger, 800-amino-acid size class,
represented by E. coli, an extra 150-amino-acid block is found
in the C-terminal domain of the protein (20) (Fig. 2). The
commonly recognized ATP binding motif GXXGXG is found
at positions 162 to 167 of B. bacilliformis GyrB, corresponding
to positions 114 to 119 of E. coli GyrB.
The structure of the B. bacilliformis GyrB is unusual in two
ways. First, in GyrBs sequenced to date, the first N-terminal
amino acid that demonstrates universal conservation through-
out bacteria is a Tyr residue represented by E. coli Tyr5, cor-
responding to Tyr53 of B. bacilliformis (Fig. 2). The side chain
of Tyr5 hydrogen bonds to the bound ATP analog (48). The
number of amino acids preceding this conserved Tyr is less
than 13 for nearly all bacteria examined to date. B. bacilliformis
GyrB is unusual in this respect in that 52 amino acid residues
precede the E. coli Tyr5 homolog, making it the longest N-
terminal extension reported to date. Only M. tuberculosis has
an N-terminal extension of this magnitude, with 50 amino acids
(Fig. 2); however, the two extensions are not homologous. The
crystal structure of the E. coli GyrB N-terminal domain com-
plexed with a nonhydrolyzable ATP analog shows that the
N-terminal 13 residues form a protrusion that interacts with
the other GyrB protomer (48). This interaction stabilizes the
dimer interface and forms part of the ATP binding site (48).
However, the N terminus is apparently not ordered in the
cocrystal structure with the coumarin inhibitor novobiocin
(26). The function of the unusually long N-terminal extensions
of M. tuberculosis and B. bacilliformis GyrBs is intriguing and
remains to be determined. A second primary structural feature
of B. bacilliformis GyrB that we have noted is Glu128 (E. coli
equivalent, Gly81). In all wild-type GyrBs reported thus far,
this residue is either glycine or aspartate, with the exception of
those found in the Mycobacteria, which have alanine or gluta-
mate at this position. In this respect, B. bacilliformis GyrB is
also more similar to the mycobacterial GyrB. This position is
one of three loci that is mutated in a novobiocin-resistant
Haloferax (Asp823Gly) (19), although it is distant from the
coumarin binding site (26). Although both B. bacilliformis and
M. tuberculosis are slow-growing bacteria and have several sim-
ilar GyrB structural features, the effect of these properties on
interactions with ATP or coumarins is unknown.
The mechanism of coumermycin A1 resistance in B. bacilli-
formis mutants was identified by sequencing PCR fragments
generated with primers amplifying the portion of the gyrB gene
that encodes the N-terminal domain. We have isolated 12
coumermycin A1-resistant mutants and have identified single
nucleotide transitions at three separate loci resulting in single
amino acid substitutions in the N-terminal domain of the GyrB
protein. Lesions detected in the resistant B. bacilliformis gyrB
genes are analogous in location and residue substitution to
previously characterized resistant gyrB genes (11, 13, 19, 39, 40,
44). The crystal structure has revealed important interactions
for each of the lesion sites. First, the side group of the E. coli
Arg136 residue (B. bacilliformis Arg184) makes critical hydro-
gen bonds with the coumarins and with E. coli Tyr5 (B. bacil-
liformis Tyr53) on the other protomer (which is involved in
ATP binding) (26). The second and third residues associated
with coumarin resistance, E. coli Gly77 (B. bacilliformis
Gly124) and E. coli Thr165 (B. bacilliformis Thr214), specifi-
cally interact with each other as well as stabilize interactions
with ATP and coumarins (26).
These data demonstrate that the B. bacilliformis DNA gyrase
B protein is a target for coumarin antibiotics. Wild-type B.
bacilliformis (MIC, 0.06 mg/ml) was shown to be more suscep-
tible to growth inhibition by coumermycin A1 than almost all
other bacteria tested (50) and is 250 times more susceptible
than E. coli (17). These data are consistent with the finding
that Bartonella is extremely susceptible to a variety of antibac-
FIG. 3. Detection of the gyrB gene in the B. bacilliformis chromosome by DNA hybridization. (A) Ethidium bromide-stained agarose gel (1%, wt/vol) containing
l HindIII size standards (lane 1), BamHI-digested chromosomal DNA of E. coli HB101 (lane 2), BamHI-digested chromosomal DNA of B. bacilliformis KC583 (lane
3), BamHI-digested chromosomal DNA of B. bacilliformis KC584 (lane 4), no DNA (lane 5), and 2,410-bp PCR fragment containing the entire B. bacilliformis gyrB
ORF. (B) The corresponding autoradiograph following DNA hybridization with the described 2,410-bp PCR fragment labeled with [32P]dCTP. The lanes are the same
as those panel A. Note the hybridization signal in both B. bacilliformis strains (lanes 3 and 4).
TABLE 2. Complementation with B. bacilliformis gyrB
E. coli strain
Growth at 42°C with the following plasmida:
None pCR2.1-TOPO pGYRB3
N99 111 111 111
N4177 1/2 1/2 111
a Growth is based upon colony size and logarithmic growth kinetics as mea-
sured by optical density at 600 nm. The temperature chosen (42°C) is the
restrictive temperature for N4177 (30). Symbols: 111, robust growth; 1/2,
slight growth.
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terial agents in vitro (27). The mutant strains demonstrated an
approximately fivefold increase in resistance levels. The MICs
for GyrB mutants represented by strains CR3, CR4, and CR9
were determined to be 0.2 mg/ml, whereas the MIC for CR5
was 0.3 mg/ml. This suggests that a Thr2143Ile substitution
confers a higher level of resistance than Thr2143Ala,
Gly1243Ser, or Arg1843Gln, consistent with findings in B.
burgdorferi (40).
The transition between the diverse thermal environments of
the arthropod vector and the human host, as well as the pre-
sentation of the verruga peruana on the extremities (,37°C),
suggests that there is a close relationship between temperature
and gene expression in B. bacilliformis. Yersinia enterocolitica
DNA gyrase mutants simulate thermoinduced alterations of
DNA supercoiling with coincident phenotypic changes (38).
Likewise, DNA topology regulated by DNA gyrase may play an
important role in the survival or virulence of B. bacilliformis in
both the vector and host, and DNA gyrase mutants may pro-
vide a method for analysis of thermoregulation.
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